Literature DB >> 16425959

Hematologic complications of HIV infection.

Elaine Sloand1.   

Abstract

Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies. Thrombotic thrombocytopenic purpura and thrombosis resulting from protein S deficiency are relatively rare complications of HIV in the United States in patients taking HAART, but are frequent in the developing world where these drugs are not available. Cytopenia, particularly anemia, are more common and result both from bone marrow failure and peripheral destruction. Hodgkin's and non-Hodgkin's lymphoma are still problematic in patients with advanced disease with high viral loads. This review will examine and discuss the diagnosis and management of the hematologic complications of HIV.

Entities:  

Mesh:

Year:  2005        PMID: 16425959

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  28 in total

1.  Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor.

Authors:  David J Auerbach; Yin Lin; Huiyi Miao; Raffaello Cimbro; Michelle J Difiore; Monica E Gianolini; Lucinda Furci; Priscilla Biswas; Anthony S Fauci; Paolo Lusso
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  The management of immune thrombocytopenic purpura.

Authors:  B I Chosamata
Journal:  Malawi Med J       Date:  2015-09       Impact factor: 0.875

3.  A review of the use of blood and blood products in HIV-infected patients.

Authors:  Karin van den Berg; James van Hasselt; Evan Bloch; Robert Crookes; James Kelley; Jonathan Berger; Charlotte Ingram; Anel Dippenaar; Rajendra Thejpal; Neil Littleton; Tersia Elliz; Gary Reubenson; Mark Cotton; Jennifer C Hull; Pamela Moodley; Yasmin Goga; William Eldridge; Moosa Patel; Eric Hefer; Arthur Bird
Journal:  South Afr J HIV Med       Date:  2012-06-07       Impact factor: 2.744

4.  Type I IFNs Act upon Hematopoietic Progenitors To Protect and Maintain Hematopoiesis during Pneumocystis Lung Infection in Mice.

Authors:  Justin R Prigge; Teri R Hoyt; Erin Dobrinen; Mario R Capecchi; Edward E Schmidt; Nicole Meissner
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

5.  Prevalence of anaemia and immunological markers among ghanaian HAART-naïve HIV-patients and those on HAART.

Authors:  W K B A Owiredu; L Quaye; N Amidu; O Addai-Mensah
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

6.  HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice.

Authors:  Christopher C Nixon; Dimitrios N Vatakis; Scott N Reichelderfer; Dhaval Dixit; Sohn G Kim; Christel H Uittenbogaart; Jerome A Zack
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

Review 7.  Evaluation and management of patients with isolated neutropenia.

Authors:  Peter E Newburger; David C Dale
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

8.  B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent.

Authors:  Teri R Hoyt; Erin Dobrinen; Irina Kochetkova; Nicole Meissner
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

Review 9.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

10.  Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort.

Authors:  A A Chaudhry; M S Sulkowski; G Chander; R D Moore
Journal:  HIV Med       Date:  2008-12-20       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.